Finally, we presented compelling evidence that preexisting anti-MeV antibodies do not impact the immunogenicity of MeV-based COVID-19 vaccine candidates containing epitope-modified H and F surface glycoproteins (MeV-MR). This evidence concerns the gene NR3C2 and COVID-19.